A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours

Florence Atrafi, Herlinde Dumez, Ron H.J. Mathijssen, Catharine W. Menke van der Houven van Oordt, Cristianne J.F. Rijcken, Rob Hanssen, Ferry A.L.M. Eskens, Patrick Schöffski

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)


Background: CPC634 is docetaxel entrapped in core-cross linked polymeric micelles. In preclinical studies, CPC634 demonstrated enhanced pharmacokinetics and improved therapeutic index. This phase I dose escalation study is the first-in-human study with CPC634. Methods: adult patients with advanced solid tumours received CPC634 intravenously either 3-weekly (Q3W) (part 1, dose range 15–100 mg/m2), 2-weekly (Q2W) (part 2, 45 mg/m2) or Q3W with dexamethasone premedication (part 3, 60 mg/m2). Results: thirty-three patients were enrolled. Skin toxicity was dose limiting (DLT) at ≥60 mg/m2 in part 1 and at 45 mg/m2 in part 2 and was the most common CPC634 related grade ≥ 3 adverse event (24%). With dexamethasone premedication no DLTs were observed at 60 mg/m2 Q3W. CPC634 exhibited a dose-proportional pharmacokinetic profile. At 60 mg/m2, the plasma area under the curve was 4067.5 ± 2974.0 ng/h/mL and the peak plasma level 217.3 ± 91.9 ng/mL with a half-life of 39.7 ± 9.4 h for released docetaxel. Conclusion: CPC634 could be administered safely upon pretreatment with dexamethasone. Cumulative skin toxicity was the main DLT. The recommended phase 2 dose was determined at 60 mg/m2 Q3W with dexamethasone premedication.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalJournal of controlled release
Publication statusPublished - 10 Sept 2020


  • Chemotherapy
  • Docetaxel
  • Drug development
  • Nanoparticles
  • Pharmacokinetics
  • Phase I
  • Tumours

Cite this